

WE TURN DATA INTO ACTION



A full-time team of clinicians develops and maintains thousands of clinical rules reflecting the latest standards of care. Every year they review:

~50 new drugs¹
~400 standards of care and treatment guidelines²

Our patented **CareEngine® technology sorts and organizes large volumes of data**

- Medical claims
- Admission Discharge Transfer
- Electronic Health Record (EHR)
- Labs
- Prescriptions
- Device
- Health assessment
- Provider feedback
- Social determinants of health



We translate and analyze the data using peer-reviewed, evidence-based **clinical analytics to find opportunities to improve care.**

Prioritized Health Actions for **MEMBERS**

Insights for **COACHES AND CLINICIANS**

Care ConsiderationSM alerts integrated in the EHR for **PROVIDERS**

In one year, we found almost

2 million gaps in care which were urgent and important³

57% were closed by providers and members³

An independently validated study⁴ of almost

1.2 million members

\$8.79 savings (1.33%) in medical and pharmacy costs per member, per month*

3.1% reduction in inpatient costs*

1.2% reduction in cardiac procedure costs*



ValidationInstitute

¹ U.S. Food and Drug Administration. Novel Drug Approvals for 2021. Available at <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>. Accessed May 13, 2022.

² ActiveHealth book of business data 2021

³ ActiveHealth book of business data for gaps in care identified between April 1, 2021 and March 31, 2022. Results include only Severity 1 (urgent) and Severity 2 (important) gaps in care. Each gap in care is a single episode.

⁴ Medicare IVL Member Study (February 2022). The study was a randomized prospective claims-based cohort study. Study group: 1,078,194 Medicare members and their providers received Care Consideration alerts from CareEngine June 2019 through June 2021. Control group: 119,785 Medicare members without Care Consideration alerts delivered. The original sample was comprised of

1,197,979 million members. The results of this study reflect cost savings in a restricted cohort where members have continuous enrollment, and excluding members with certain conditions (HIV/AIDS, Crohn's, cystic fibrosis, hemophilia and bleeding disorders, multiple sclerosis, Parkinson's, Sickle cell, Lupus). Longitudinal view of Care Consideration alert closure rates shows resolution difference in the first 3 quarters driving reduction in total costs. The incremental gap closure rate is 0.6% higher in treatment group than in control group, which is statistically significant between the two groups at $p \leq .05$.

Services are provided by ActiveHealth Management, Inc. Our programs, care team and care managers do not provide diagnostic or direct treatment services. We assist you in getting the care you need, and our program is not a substitute for the medical treatment and/or instructions provided by your health care providers.

ActiveHealth data can help improve outcomes and lower costs. Visit us at **ActiveHealth.com** to

LEARN MORE